Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics Q1 revenue rises 5.6% to $339.4 million; raises fiscal 2027 guidance

Positive Impact 4 of 5 guidance Written later

Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6%, with GAAP earnings of $0.72 per diluted share versus $0.70 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 4% to 7% from 3% to 6%, though GAAP net income fell 3.0% to $33.0 million.

Key points

  • Q1 fiscal 2027 revenue was $339.4 million, up 5.6%; organic revenue growth was 5.9%.
  • GAAP diluted EPS was $0.72 versus $0.70; adjusted diluted EPS was $1.14, up 3.6%.
  • Organic revenue growth guidance was raised to 4% to 7% from 3% to 6%; reported revenue guidance was raised to 5% to 8% from 4% to 7%.
  • Free cash flow was $39.1 million, up $36.6 million; cash on hand was $223.4 million as of June 27, 2026.

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECAug 6, 2026, 6:07 AM ET
Accession number0000313143-26-000118

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.